BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Park JY, Ahn SH, Yoon YJ, Kim JK, Lee HW, Lee DY, Chon CY, Moon YM, Han K. Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma. Cancer 2007;110:129-37. [DOI: 10.1002/cncr.22759] [Cited by in Crossref: 78] [Cited by in F6Publishing: 72] [Article Influence: 5.2] [Reference Citation Analysis]
Number Citing Articles
1 Sonoda A, Nitta N, Ohta S, Nitta-seko A, Morikawa S, Tabata Y, Takahashi M, Murata K. Controlled Release and Antitumor Effect of Pluronic F127 Mixed with Cisplatin in a Rabbit Model. Cardiovasc Intervent Radiol 2010;33:135-42. [DOI: 10.1007/s00270-009-9741-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
2 Seki H, Ozaki T, Ooi H. Dual-phase CT angiography through the port-catheter system for hepatic arterial infusion chemotherapy using multislice CT: assessment of system dysfunction and impact on predicting clinical problems. Acta Radiol 2012;53:1026-34. [DOI: 10.1258/ar.2012.120174] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
3 Kim do Y, Ahn SH, Kim SU, Choi SB, Lee KH, Park MS, Park JY, Lee do Y, Han KH, Kim KS. Adjuvant hepatic arterial infusional chemotherapy with 5-fluorouracil and cisplatin after curative resection of hepatocellular carcinoma. Oncology. 2011;81:184-191. [PMID: 22067673 DOI: 10.1159/000333827] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
4 Chen P, Furuse J, Han K, Hsu C, Lim H, Moon H, Qin S, Ye S, Yeoh E, Yeo W. Issues and controversies of hepatocellular carcinoma-targeted therapy clinical trials in Asia: experts' opinion: HCC clinical trials in Asia. Liver International 2010;30:1427-38. [DOI: 10.1111/j.1478-3231.2010.02292.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 2.1] [Reference Citation Analysis]
5 He MK, Zou RH, Li QJ, Zhou ZG, Shen JX, Zhang YF, Yu ZS, Xu L, Shi M. Phase II Study of Sorafenib Combined with Concurrent Hepatic Arterial Infusion of Oxaliplatin, 5-Fluorouracil and Leucovorin for Unresectable Hepatocellular Carcinoma with Major Portal Vein Thrombosis. Cardiovasc Intervent Radiol. 2018;41:734-743. [PMID: 29327075 DOI: 10.1007/s00270-017-1874-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
6 Ikeda M, Morizane C, Ueno M, Okusaka T, Ishii H, Furuse J. Chemotherapy for hepatocellular carcinoma: current status and future perspectives. Japanese Journal of Clinical Oncology 2018;48:103-14. [DOI: 10.1093/jjco/hyx180] [Cited by in Crossref: 78] [Cited by in F6Publishing: 79] [Article Influence: 15.6] [Reference Citation Analysis]
7 Song DS, Bae SH, Song MJ, Lee SW, Kim HY, Lee YJ, Oh JS, Chun HJ, Lee HG, Choi JY, Yoon SK. Hepatic arterial infusion chemotherapy in hepatocellular carcinoma with portal vein tumor thrombosis. World J Gastroenterol 2013; 19(29): 4679-4688 [PMID: 23922465 DOI: 10.3748/wjg.v19.i29.4679] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
8 Song IH, Kim KS. Current status of liver diseases in Korea: hepatocellular carcinoma. Korean J Hepatol. 2009;15 Suppl 6:S50-S59. [PMID: 20037280 DOI: 10.3350/kjhep.2009.15.s6.s50] [Cited by in Crossref: 40] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
9 Song MJ. Hepatic artery infusion chemotherapy for advanced hepatocellular carcinoma. World J Gastroenterol 2015; 21(13): 3843-3849 [PMID: 25852268 DOI: 10.3748/wjg.v21.i13.3843] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 23] [Article Influence: 3.7] [Reference Citation Analysis]
10 Yamashita T. Current status of hepatocellular carcinoma treatment in Japan: hepatic arterial infusion chemotherapy. Clin Drug Investig 2012;32 Suppl 2:15-23. [PMID: 22873624 DOI: 10.1007/BF03265493] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
11 Zhuang BW, Li W, Xie XH, Hu HT, Lu MD, Xie XY. Sorafenib versus hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: a systematic review and meta-analysis. Jpn J Clin Oncol 2019;49:845-55. [PMID: 31063184 DOI: 10.1093/jjco/hyz069] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
12 Nagano H, Wada H, Kobayashi S, Marubashi S, Eguchi H, Tanemura M, Tomimaru Y, Osuga K, Umeshita K, Doki Y. Long-term outcome of combined interferon-α and 5-fluorouracil treatment for advanced hepatocellular carcinoma with major portal vein thrombosis. Oncology. 2011;80:63-69. [PMID: 21659784 DOI: 10.1159/000328281] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 2.3] [Reference Citation Analysis]
13 Han S, Choi HJ, Beom SH, Kim HR, Lee H, Lee JS, Lee HW, Park JY, Kim SU, Kim DY, Ahn SH, Han KH, Seong J, Won JY, Kim BK. Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma. J Cancer Res Clin Oncol 2021;147:3123-33. [PMID: 33893539 DOI: 10.1007/s00432-021-03632-4] [Reference Citation Analysis]
14 Liu S, Bu X, Kan A, Luo L, Xu Y, Chen H, Lin X, Lai Z, Wen D, Huang L, Shi M. SP1-induced lncRNA DUBR promotes stemness and oxaliplatin resistance of hepatocellular carcinoma via E2F1-CIP2A feedback. Cancer Lett 2021;528:16-30. [PMID: 34958891 DOI: 10.1016/j.canlet.2021.12.026] [Reference Citation Analysis]
15 Song DS, Song MJ, Bae SH, Chung WJ, Jang JY, Kim YS, Lee SH, Park JY, Yim HJ, Cho SB, Park SY, Yang JM. A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. J Gastroenterol. 2015;50:445-454. [PMID: 25027973 DOI: 10.1007/s00535-014-0978-3] [Cited by in Crossref: 63] [Cited by in F6Publishing: 66] [Article Influence: 7.9] [Reference Citation Analysis]
16 Liu S, Lai J, Lyu N, Xie Q, Cao H, Chen D, He M, Zhang B, Zhao M. Effects of Antiviral Therapy on HBV Reactivation and Survival in Hepatocellular Carcinoma Patients Undergoing Hepatic Artery Infusion Chemotherapy. Front Oncol 2020;10:582504. [PMID: 33614477 DOI: 10.3389/fonc.2020.582504] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Shao Y, Liang P, Wu Y, Huang C, Huang K, Cheng JC, Hsu C, Hsu C, Cheng A, Lin Z. A pilot study of hepatic arterial infusion of chemotherapy for patients with advanced hepatocellular carcinoma who have failed anti-angiogenic therapy. Liver Int 2013;33:1413-9. [DOI: 10.1111/liv.12207] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
18 Kim DY, Han KH. How to improve treatment outcomes for hepatocellular carcinoma of intermediate and advanced stage. Dig Dis 2012;30:598-602. [PMID: 23258101 DOI: 10.1159/000343088] [Cited by in Crossref: 12] [Cited by in F6Publishing: 63] [Article Influence: 1.2] [Reference Citation Analysis]
19 Sinn DH, Cho JY, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC. Different survival of Barcelona clinic liver cancer stage C hepatocellular carcinoma patients by the extent of portal vein invasion and the type of extrahepatic spread. PLoS One. 2015;10:e0124434. [PMID: 25923439 DOI: 10.1371/journal.pone.0124434] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 4.0] [Reference Citation Analysis]
20 Han KH, Seong J, Kim JK, Ahn SH, Lee do Y, Chon CY. Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis. Cancer. 2008;113:995-1003. [PMID: 18615601 DOI: 10.1002/cncr.23684] [Cited by in Crossref: 109] [Cited by in F6Publishing: 99] [Article Influence: 7.8] [Reference Citation Analysis]
21 Rathore R, Safran H, Soares G, Dubel G, McNulty B, Ahn S, Iannitti D, Kennedy T. Phase I study of hepatic arterial infusion of oxaliplatin in advanced hepatocellular cancer: a brown university oncology group study. Am J Clin Oncol. 2010;33:43-46. [PMID: 19687731 DOI: 10.1097/coc.0b013e31819d8668] [Cited by in Crossref: 18] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
22 Jung KS, Kim SU, Ahn SH, Park YN, Kim DY, Park JY, Chon CY, Choi EH, Han KH. Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan). Hepatology. 2011;53:885-894. [PMID: 21319193 DOI: 10.1002/hep.24121] [Cited by in Crossref: 256] [Cited by in F6Publishing: 240] [Article Influence: 23.3] [Reference Citation Analysis]
23 He M, Li Q, Zou R, Shen J, Fang W, Tan G, Zhou Y, Wu X, Xu L, Wei W, Le Y, Zhou Z, Zhao M, Guo Y, Guo R, Chen M, Shi M. Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial. JAMA Oncol. 2019;5:953-960. [PMID: 31070690 DOI: 10.1001/jamaoncol.2019.0250] [Cited by in Crossref: 62] [Cited by in F6Publishing: 58] [Article Influence: 31.0] [Reference Citation Analysis]
24 Park MS, Kim SU, Park JY, Kim do Y, Ahn SH, Han KH, Chon CY, Seong J. Combination treatment of localized concurrent chemoradiation therapy and transarterial chemoembolization in locally advanced hepatocellular carcinoma with intrahepatic metastasis. Cancer Chemother Pharmacol. 2013;71:165-173. [PMID: 23079897 DOI: 10.1007/s00280-012-1993-9] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
25 Han KH, Park JY. Systemic treatment in advanced/metastatic hepatocellular carcinoma in the era of targeted therapy. J Gastroenterol Hepatol 2010;25:1023-5. [PMID: 20594213 DOI: 10.1111/j.1440-1746.2010.06359.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
26 Nakano M, Niizeki T, Nagamatsu H, Tanaka M, Kuromatsu R, Satani M, Okamura S, Iwamoto H, Shimose S, Shirono T, Noda Y, Koga H, Torimura T; Kurume Liver Cancer Study Group of Japan. Clinical effects and safety of intra-arterial infusion therapy of cisplatin suspension in lipiodol combined with 5-fluorouracil versus sorafenib, for advanced hepatocellular carcinoma with macroscopic vascular invasion without extra-hepatic spread: A prospective cohort study. Mol Clin Oncol 2017;7:1013-20. [PMID: 29285366 DOI: 10.3892/mco.2017.1442] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
27 Ueda S, Shirabe K, Morita K, Umeda K, Kayashima H, Uchiyama H, Soejima Y, Taketomi A, Maehara Y. Evaluation of ERCC1 Expression for Cisplatin Sensitivity in Human Hepatocellular Carcinoma. Ann Surg Oncol 2011;18:1204-11. [DOI: 10.1245/s10434-010-1414-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
28 Hamaoka M, Kobayashi T, Kuroda S, Iwako H, Okimoto S, Kimura T, Aikata H, Nagata Y, Chayama K, Ohdan H. Hepatectomy after down-staging of hepatocellular carcinoma with portal vein tumor thrombus using chemoradiotherapy: A retrospective cohort study. International Journal of Surgery 2017;44:223-8. [DOI: 10.1016/j.ijsu.2017.06.082] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
29 Han KH, Park JY. Chemotherapy for advanced hepatocellular carcinoma. J Gastroenterol Hepatol 2008;23:682-4. [PMID: 18410601 DOI: 10.1111/j.1440-1746.2008.05444.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
30 Nishikawa H, Osaki Y, Kita R, Kimura T. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in Japan. Cancers (Basel) 2012;4:165-83. [PMID: 24213234 DOI: 10.3390/cancers4010165] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
31 Shin HS, Kim SU, Park JY, Kim DY, Han KH, Chon CY, Baatarkhuu O, Ahn SH. Antiviral efficacy of lamivudine versus entecavir in patients with hepatitis B virus-related advanced hepatocellular carcinoma. J Gastroenterol Hepatol 2012;27:1528-34. [PMID: 22497450 DOI: 10.1111/j.1440-1746.2012.07145.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
32 Jeong SW, Jang JY, Lee JE, Lee SH, Kim SG, Cha SW, Kim YS, Cho YD, Kim HS, Kim BS. The efficacy of hepatic arterial infusion chemotherapy as an alternative to sorafenib in advanced hepatocellular carcinoma. Asia Pac J Clin Oncol. 2012;8:164-171. [PMID: 22524575 DOI: 10.1111/j.1743-7563.2012.01543.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
33 Kim BK, Kim DY, Byun HK, Choi HJ, Beom SH, Lee HW, Kim SU, Park JY, Ahn SH, Seong J, Han KH. Efficacy and Safety of Liver-Directed Concurrent Chemoradiotherapy and Sequential Sorafenib for Advanced Hepatocellular Carcinoma: A Prospective Phase 2 Trial. Int J Radiat Oncol Biol Phys 2020;107:106-15. [PMID: 32084526 DOI: 10.1016/j.ijrobp.2020.01.027] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
34 Otani S, Takeda S, Yamada S, Sakakima Y, Sugimoto H, Nomoto S, Kasuya H, Kanazumi N, Nagasaka T, Nakao A. The tumor suppressor NPRL2 in hepatocellular carcinoma plays an important role in progression and can be served as an independent prognostic factor. J Surg Oncol. 2009;100:358-363. [PMID: 19274676 DOI: 10.1002/jso.21241] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
35 Vu NB, Nguyen TT, Tran LC, Do CD, Nguyen BH, Phan NK, Pham PV. Doxorubicin and 5-fluorouracil resistant hepatic cancer cells demonstrate stem-like properties. Cytotechnology. 2013;65:491-503. [PMID: 23104270 DOI: 10.1007/s10616-012-9511-9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
36 Spada F, Fazio N, Bonomo G, Monfardini L, Vigna PD, Radice D, Boselli S, Orsi F. Hepatic intra-arterial chemotherapy in patients with advanced primary liver tumours. Ecancermedicalscience 2012;6:280. [PMID: 23226162 DOI: 10.3332/ecancer.2012.280] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
37 Gao Y, Wang PX, Cheng JW, Sun YF, Hu B, Guo W, Zhou KQ, Yin Y, Li YC, Wang J, Huang JF, Qiu SJ, Zhou J, Fan J, Yang XR. Chemotherapeutic perfusion of portal vein after tumor thrombectomy and hepatectomy benefits patients with advanced hepatocellular carcinoma: A propensity score-matched survival analysis. Cancer Med 2019;8:6933-44. [PMID: 31566899 DOI: 10.1002/cam4.2556] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
38 Chun YH, Kim SU, Park JY, Kim DY, Han KH, Chon CY, Kim BK, Choi GH, Kim KS, Choi JS, Ahn SH. Prognostic value of the 7th edition of the AJCC staging system as a clinical staging system in patients with hepatocellular carcinoma. Eur J Cancer. 2011;47:2568-2575. [PMID: 21835608 DOI: 10.1016/j.ejca.2011.07.002] [Cited by in Crossref: 42] [Cited by in F6Publishing: 46] [Article Influence: 3.8] [Reference Citation Analysis]
39 Lee BH, Lee DS, Cho CW, Yun SS. Role and limitation of neoadjuvant hepatic arterial infusion chemotherapy in advanced hepatocelluar carcinoma patients with Child-Pugh class A. World J Surg Oncol 2019;17:143. [PMID: 31416447 DOI: 10.1186/s12957-019-1685-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
40 Zhang YA, Zhu CW. Management of advanced hepatocellular carcinoma. Shijie Huaren Xiaohua Zazhi 2010; 18(12): 1250-1254 [DOI: 10.11569/wcjd.v18.i12.1250] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
41 Kim HY, Kim JD, Bae SH, Park JY, Han KH, Woo HY, Choi JY, Yoon SK, Jang BK, Hwang JS, Kim SG, Kim YS, Seo YS, Yim HJ, Um SH; Korean Liver Cancer Study Group. A comparative study of high-dose hepatic arterial infusion chemotherapy and transarterial chemoembolization using doxorubicin for intractable, advanced hepatocellular carcinoma. Korean J Hepatol 2010;16:355-61. [PMID: 21415578 DOI: 10.3350/kjhep.2010.16.4.355] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
42 Ma MC, Chen YY, Li SH, Cheng YF, Wang CC, Chiu TJ, Pei SN, Liu CT, Huang TL, Huang CH, Su YL, Chen YH, Lu SN, Rau KM. Intra-arterial chemotherapy with doxorubicin and cisplatin is effective for advanced hepatocellular cell carcinoma. ScientificWorldJournal 2014;2014:160138. [PMID: 24967421 DOI: 10.1155/2014/160138] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
43 Kataoka J, Shiraha H, Horiguchi S, Sawahara H, Uchida D, Nagahara T, Iwamuro M, Morimoto H, Takeuchi Y, Kuwaki K, Onishi H, Nakamura S, Takaki A, Nouso K, Yagi T, Yamamoto K, Okada H. Loss of Runt-related transcription factor 3 induces resistance to 5-fluorouracil and cisplatin in hepatocellular carcinoma. Oncol Rep 2016;35:2576-82. [PMID: 26985715 DOI: 10.3892/or.2016.4681] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
44 Lee MH, Kim SU, Kim DY, Ahn SH, Choi EH, Lee KH, Lee DY, Seong J, Han K, Chon CY, Park JY. Early on-treatment predictions of clinical outcomes using alpha-fetoprotein and des-gamma-carboxy prothrombin responses in patients with advanced hepatocellular carcinoma: Predictors in hepatocellular carcinoma. Journal of Gastroenterology and Hepatology 2012;27:313-22. [DOI: 10.1111/j.1440-1746.2011.06867.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
45 Lee S, Kim BK, Kim SU, Park SY, Kim JK, Lee HW, Park JY, Kim do Y, Ahn SH, Tak WY. Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy: a Korean multicenter study. J Gastroenterol Hepatol. 2014;29:1463-1469. [PMID: 25273508 DOI: 10.1111/jgh.12542] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
46 Chen F, Fang Y, Zhao R, Le J, Zhang B, Huang R, Chen Z, Shao J. Evolution in medicinal chemistry of sorafenib derivatives for hepatocellular carcinoma. Eur J Med Chem 2019;179:916-35. [PMID: 31306818 DOI: 10.1016/j.ejmech.2019.06.070] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
47 Choi C, Choi GH, Kim TH, Tanaka M, Meng MB, Seong J. Multimodality Management for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma. Liver Cancer 2014;3:405-16. [PMID: 26280002 DOI: 10.1159/000343861] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
48 Han S, Lee HW, Park JY, Kim SU, Kim DY, Ahn SH, Han KH, Seong J, Won JY, Han DH, Kim BK. Appraisal of Long-Term Outcomes of Liver-Directed Concurrent Chemoradiotherapy for Hepatocellular Carcinoma with Major Portal Vein Invasion. J Hepatocell Carcinoma 2020;7:403-12. [PMID: 33365287 DOI: 10.2147/JHC.S276528] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Hiramine Y, Uto H, Imamura Y, Tabu K, Baba Y, Hiwaki T, Sho Y, Tahara K, Higashi H, Tamai T. Sorafenib and hepatic arterial infusion chemotherapy for unresectable advanced hepatocellular carcinoma: A comparative study. Exp Ther Med. 2011;2:433-441. [PMID: 22977522 DOI: 10.3892/etm.2011.237] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
50 Arii S, Sata M, Sakamoto M, Shimada M, Kumada T, Shiina S, Yamashita T, Kokudo N, Tanaka M, Takayama T, Kudo M. Management of hepatocellular carcinoma: Report of Consensus Meeting in the 45th Annual Meeting of the Japan Society of Hepatology (2009). Hepatol Res. 2010;40:667-685. [PMID: 20633193 DOI: 10.1111/j.1872-034x.2010.00673.x] [Cited by in Crossref: 129] [Cited by in F6Publishing: 47] [Article Influence: 11.7] [Reference Citation Analysis]
51 Han DH, Joo DJ, Kim MS, Choi GH, Choi JS, Park YN, Seong J, Han KH, Kim SI. Living Donor Liver Transplantation for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis after Concurrent Chemoradiation Therapy. Yonsei Med J. 2016;57:1276-1281. [PMID: 27401662 DOI: 10.3349/ymj.2016.57.5.1276] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
52 Kim KH, Kim MS, Chang JS, Han KH, Kim do Y, Seong J. Therapeutic benefit of radiotherapy in huge (≥10 cm) unresectable hepatocellular carcinoma. Liver Int. 2014;34:784-794. [PMID: 24330457 DOI: 10.1111/liv.12436] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
53 Kim BK, Kim SU, Park JY, Kim DY, Ahn SH, Park MS, Kim EH, Seong J, Lee DY, Han K. Applicability of BCLC stage for prognostic stratification in comparison with other staging systems: single centre experience from long-term clinical outcomes of 1717 treatment-naïve patients with hepatocellular carcinoma. Liver Int 2012;32:1120-7. [DOI: 10.1111/j.1478-3231.2012.02811.x] [Cited by in Crossref: 67] [Cited by in F6Publishing: 75] [Article Influence: 6.7] [Reference Citation Analysis]
54 Niizeki T, Sumie S, Torimura T, Kurogi J, Kuromatsu R, Iwamoto H, Aino H, Nakano M, Kawaguchi A, Kakuma T, Sata M. Serum vascular endothelial growth factor as a predictor of response and survival in patients with advanced hepatocellular carcinoma undergoing hepatic arterial infusion chemotherapy. J Gastroenterol 2012;47:686-95. [DOI: 10.1007/s00535-012-0555-6] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 3.3] [Reference Citation Analysis]
55 Cha CH, Saif MW, Yamane BH, Weber SM. Hepatocellular carcinoma: Current management. Curr Probl Surg. 2010;47:10-67. [PMID: 19963083 DOI: 10.1067/j.cpsurg.2009.09.003] [Cited by in Crossref: 56] [Cited by in F6Publishing: 45] [Article Influence: 4.7] [Reference Citation Analysis]
56 Lee S, Kim BK, Kim SU, Park Y, Chang S, Park JY, Kim do Y, Ahn SH, Chon CY, Han KH. Efficacy of sorafenib monotherapy versus sorafenib-based loco-regional treatments in advanced hepatocellular carcinoma. PLoS One. 2013;8:e77240. [PMID: 24155932 DOI: 10.1371/journal.pone.0077240] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
57 Woo HY, Youn JM, Bae SH, Jang JW, Cha JH, Kim HL, Chun HJ, Choi BG, Choi JY, Yoon SK. Efficacy and safety of metronomic chemotherapy for patients with advanced primary hepatocellular carcinoma with major portal vein tumor thrombosis. Korean J Hepatol 2012;18:32-40. [PMID: 22511901 DOI: 10.3350/kjhep.2012.18.1.32] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
58 Kim DY. Can metronomic chemotherapy be an alternative to sorafenib in advanced hepatocellular carcinoma? Clin Mol Hepatol 2017;23:123-4. [PMID: 28669140 DOI: 10.3350/cmh.2017.0107] [Reference Citation Analysis]
59 Fazry S, Noordin MAM, Sanusi S, Noor MM, Aizat WM, Lazim AM, Dyari HRE, Jamar NH, Remali J, Othman BA, Law D, Sidik NM, Cheah YH, Lim YC. Cytotoxicity and Toxicity Evaluation of Xanthone Crude Extract on Hypoxic Human Hepatocellular Carcinoma and Zebrafish (Danio rerio) Embryos. Toxics 2018;6:E60. [PMID: 30304811 DOI: 10.3390/toxics6040060] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
60 Steiner K, Papadopoulou A, Yu D. The role of interventional radiology in the treatment of hepatocellular carcinoma. Semin Ultrasound CT MR 2013;34:89-101. [PMID: 23395321 DOI: 10.1053/j.sult.2012.11.008] [Reference Citation Analysis]
61 Song X, He Y, Liang H, Han M, Shao Z. INTRABEAM intraoperative radiotherapy combined with portal vein infusion chemotherapy for treating hepatocellular carcinoma with portal vein tumor thrombus. BMC Surg 2020;20:174. [PMID: 32738882 DOI: 10.1186/s12893-020-00836-2] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
62 Tajiri K, Kawai K, Minemura M, Yasumura S, Hosokawa A, Kawabe H, Tomizawa G, Sugiyama T. Neutrophil/lymphocyte ratio as a prognostic indicator of hepatic arterial infusion chemotherapy with arterial cisplatin plus continuous 5-fluorouracil. Hepatol Res 2015;45:755-63. [PMID: 25196816 DOI: 10.1111/hepr.12417] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
63 Li MF, Leung HW, Chan AL, Wang SY. Network meta-analysis of treatment regimens for inoperable advanced hepatocellular carcinoma with portal vein invasion. Ther Clin Risk Manag. 2018;14:1157-1168. [PMID: 30013351 DOI: 10.2147/tcrm.s162898] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
64 Yoo EJ, Shin HS, Kim SU, Joo DJ, Park JY, Choi GH, Kim DY, Ahn SH, Seong J, Koh MJ, Han KH, Chon CY. Orthotopic liver transplantation after the combined use of locoregional therapy and sorafenib for advanced hepatocellular carcinoma. Onco Targets Ther 2013;6:755-9. [PMID: 23836988 DOI: 10.2147/OTT.S45602] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
65 Kim B, Won JH, Kim J, Kwon Y, Cho HJ, Huh J, Kim JK. Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma: Radiologic and Clinical Factors Predictive of Survival. AJR Am J Roentgenol 2021;216:1566-73. [PMID: 33852336 DOI: 10.2214/AJR.20.23213] [Reference Citation Analysis]
66 Golfieri R, Bargellini I, Spreafico C, Trevisani F. Patients with Barcelona Clinic Liver Cancer Stages B and C Hepatocellular Carcinoma: Time for a Subclassification. Liver Cancer 2019;8:78-91. [PMID: 31019899 DOI: 10.1159/000489791] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
67 Ishikawa T. Future perspectives on the treatment of hepatocellular carcinoma with cisplatin. World J Hepatol 2009; 1(1): 8-16 [PMID: 21160960 DOI: 10.4254/wjh.v1.i1.8] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.0] [Reference Citation Analysis]
68 Woo HY, Bae SH, Park JY, Han KH, Chun HJ, Choi BG, Im HU, Choi JY, Yoon SK, Cheong JY. A randomized comparative study of high-dose and low-dose hepatic arterial infusion chemotherapy for intractable, advanced hepatocellular carcinoma. Cancer Chemother Pharmacol. 2010;65:373-382. [PMID: 19763572 DOI: 10.1007/s00280-009-1126-2] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 3.2] [Reference Citation Analysis]
69 Uka K, Aikata H, Takaki S, Kawaoka T, Saneto H, Miki D, Takahashi S, Toyota N, Ito K, Chayama K. Systemic gemcitabine combined with intra-arterial low-dose cisplatin and 5-fluorouracil for advanced hepatocellular carcinoma: Seven cases. World J Gastroenterol 2008; 14(16): 2602-2608 [PMID: 18442216 DOI: 10.3748/wjg.14.2602] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
70 Zaitsu J, Yamasaki T, Saeki I, Harima Y, Iwamoto T, Harima Y, Matsumoto T, Urata Y, Hidaka I, Marumoto Y. Serum transferrin as a predictor of prognosis for hepatic arterial infusion chemotherapy in advanced hepatocellular carcinoma. Hepatol Res. 2014;44:481-490. [PMID: 23607437 DOI: 10.1111/hepr.12141] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
71 Kim BK, Park JY, Choi HJ, Kim DY, Ahn SH, Kim JK, Lee DY, Lee KH, Han KH. Long-term clinical outcomes of hepatic arterial infusion chemotherapy with cisplatin with or without 5-fluorouracil in locally advanced hepatocellular carcinoma. J Cancer Res Clin Oncol. 2011;137:659-667. [PMID: 20552225 DOI: 10.1007/s00432-010-0917-5] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 3.2] [Reference Citation Analysis]
72 Han K, Kim JH, Ko GY, Gwon DI, Sung KB. Treatment of hepatocellular carcinoma with portal venous tumor thrombosis: A comprehensive review. World J Gastroenterol 2016; 22(1): 407-416 [PMID: 26755886 DOI: 10.3748/wjg.v22.i1.407] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 41] [Article Influence: 6.2] [Reference Citation Analysis]
73 Kim DY. Which treatment modality should we choose for advanced hepatocellular carcinoma? Korean J Hepatol 2010;16:353-4. [PMID: 21415577 DOI: 10.3350/kjhep.2010.16.4.353] [Reference Citation Analysis]
74 Kim BK, Han K, Ahn SH. Prevention of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Virus Infection. Oncology 2011;81:41-9. [DOI: 10.1159/000333258] [Cited by in Crossref: 21] [Cited by in F6Publishing: 26] [Article Influence: 1.9] [Reference Citation Analysis]
75 Cho IR, Lee HW, Song KJ, Kim BK, Kim SU, Kim DY, Ahn SH, Seong J, Han KH, Park JY. Conditional survival estimate in patients with Barcelona Clinic Liver Cancer stage B/C hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy with/without concurrent radiotherapy. Oncotarget 2017;8:79914-26. [PMID: 29108373 DOI: 10.18632/oncotarget.20321] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
76 Yamashita T, Arai K, Sunagozaka H, Ueda T, Terashima T, Yamashita T, Mizukoshi E, Sakai A, Nakamoto Y, Honda M. Randomized, phase II study comparing interferon combined with hepatic arterial infusion of fluorouracil plus cisplatin and fluorouracil alone in patients with advanced hepatocellular carcinoma. Oncology. 2011;81:281-290. [PMID: 22133996 DOI: 10.1159/000334439] [Cited by in Crossref: 49] [Cited by in F6Publishing: 45] [Article Influence: 4.5] [Reference Citation Analysis]
77 Shao YY, Huang CC, Liang PC, Lin ZZ. Hepatic arterial infusion of chemotherapy for advanced hepatocellular carcinoma. Asia Pac J Clin Oncol 2010;6:80-8. [PMID: 20565419 DOI: 10.1111/j.1743-7563.2010.01287.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]